Lizzy Smyth @LizzySmyth1 Twitter profile

Last Seen Profiles

@AJFDripLord

@ViralBarat

@Kingstyler88

@CiudadFuturaOK

@sama_dnl

@poisonouslilie

@JimGriffin64

@bit2me

@justice19831119

@AsHKaNAkai

@joyciebabie_

@CencoRdc

@lu_robar

@Cheezy_UNI

@pengen_stw

@k_allamjonov

@Tpcatsbear

@switixs

@arnelareglo75

@MyLovelyPlanet1

@JairusOwin

@SOkikawa45169

@PalAthletics

@Aunt_BeeS_Ass

@DaBurna15

@factsontarun

@kobo_360

@Imageshackdian4

@Trheamorse7

@_cfc_sam

@HMarinaro21

@putrategar2709

@MyLovelyPlanet1

@nunotrepa

@aini_butt

@ChronicleLabs

Lizzy Smyth

@LizzySmyth1

2 years

The waterfall plot that wins ESMO! Well done @MyriamChalabi ! #ESMO22 @myESMO

8

101

494

Lizzy Smyth

@LizzySmyth1

3 years

Outstanding new science at #ESMO21 💥CLD 18.2 CAR-T cells effective in GI cancers 💥 ORR 61% in 3L+ #gastriccancer #ESMO21 @myESMO @OncoAlert

2

89

255

Lizzy Smyth

@LizzySmyth1

1 year

Another day, another practice-changing trial in gastric cancer 👏👏👏 Thanks to @myESMO for allowing me to discuss KEYNOTE 859 with @FlorianLordick & @BHenickMD ➡️KEYNOTE-859 met the OS primary endpoint in the ITT (all-comer population)

10

65

237

Lizzy Smyth

@LizzySmyth1

4 years

Practice changing 3 month+ OS gain for CPS5 patients in CheckMate649 🏆🏆🏆 Biggest study ever in #stomachcancer ! Breaking through the one year barrier is meaningful in gastric cancer trials. #ESMO2020

9

63

222

Lizzy Smyth

@LizzySmyth1

2 years

So happy to meet my #EORTC friends in Brussels! Today I was elected next EORTC GI Trials Group Chair 😊 I'd like to say thank you everyone who has supported me on my journey from early career investigator to this role. Now I want to give that support back and #fightcancer

32

18

215

Lizzy Smyth

@LizzySmyth1

2 years

At last!!! ESMO Gastric Cancer Guidelines 2022 👏👏👏 So proud to work with this awesome team!! @FlorianLordick @ArndtVogel @tfleitask @myESMO

2

52

187

Lizzy Smyth

@LizzySmyth1

3 years

New treatments for KRAS G12C mt mCRC on the horizon. #ESMO21 Presidential session Adagrasib + cetuximab ORR 43% @myESMO @OncoAlert

0

42

146

Lizzy Smyth

@LizzySmyth1

9 months

#ESMO24 Upper GI track is hot, hot hot 🔥🔥🔥 Join us for a BLOCKBUSTER oral session at 2pm 20/10 to answer some BIG questions... 🎯 ICI in operable GEA. YES or NO? 🎯 Surgery in operable ESCC. Do we need it? 🎯 HER2 + PD-1 in 1L GEA. A new standard? See you in Madrid!

2

40

146

Lizzy Smyth

@LizzySmyth1

2 years

I'm very proud of the only girl on the pitch 🥰 #beatfabrice #ESMO22 #women4oncology @myESMO

5

138

Lizzy Smyth

@LizzySmyth1

3 years

#ESMO21 Presidential Session CheckMate649 - a practice changing trial ☑️ 1L nivolumab-chemo shows sustained OS benefit for PD-L1 CPS >5 with longer follow up ❌ 1L nivolumab-ipilimumab does not improve OS compared to chemo alone. @myESMO @YJanjigianMD @OncoAlert

1

43

120

Lizzy Smyth

@LizzySmyth1

1 year

So pleased to see this in print at last 👏👏 DESTINY Gastric 02: trastuzumab deruxtecan in 2L non-Asian gastroesophageal adenocarcinoma ➡️ORR 38% ➡️median OS > 1 year (x2 better than chemotherapy!) A positive new option for #GastricCancer patients

3

40

118

Lizzy Smyth

@LizzySmyth1

1 year

This is so important...,👇👇 Olanzapine works really well for my oesophageal and gastric cancer patients. Better nutrition = better quality of life. Please share this evidence based practice with your oncology colleagues 👍

Sharlene Gill, MD, MPH, MBA, FASCO

@GillSharlene

1 year

👇will change my practice today RDBPCT, N= 124 #gastric #HPB #lung #cancer @JCO_ASCO 📌 Olanzapine 2.5mg/day ⬆️ appetite, weight and QoL ⭐️ simple inexpensive intervention for a common and difficult problem for our pts with #GIcancer Congrats to the study team 🇮🇳 🙏

13

211

502

4

38

119

Lizzy Smyth

@LizzySmyth1

3 years

Excited to see this in print 🎉👏👏 ➡️Breaking down the results and relevance of recent gastroesophageal cancer immunotherapy trials in @Annals_Oncology with @tfleitask @ValeGamberdella and @AndresC27622123 @CRUKCamAero

5

28

96

Lizzy Smyth

@LizzySmyth1

2 years

👏🎉🎊 Incredibly proud today of my other half @ElisaFontana83 who has just been appointed Medical Director at Sarah Cannon Research Institute UK 👏👩‍❤️‍👩🎉 What an amazing achievement! And also Secretary of #EORTC GI Trials Group. #clinicaltrials 👸 @YJanjigianMD @FlorianLordick

16

5

93

Lizzy Smyth

@LizzySmyth1

8 months

📢📢 Less than a week to go until #ESMO23 ⏳ @myESMO asked the Upper GI track chair 👩‍⚕️ to share some upcoming highlights below ⬇️ Whether you're on a ✈️, 🚝 or watching 💻 Friday 2pm CET is when the transformative Upper GI starts...see you in Madrid....

4

24

94

Lizzy Smyth

@LizzySmyth1

4 years

Very proud of our new Lancet Seminar on #GastricCancer . Thanks to my wonderful #ESMO and #EORTC collaborators @FlorianLordick , Magnus Nilsson, Heike Grabsch and Nicole van Grieken!

3

23

81

Lizzy Smyth

@LizzySmyth1

9 months

👀.....NeoAegis results in @LancetGastroHep Great academic study (well done 🇮🇪!) but results overtaken by changes in standard of care. Is the equation for perioperative OG cancer like this? ECX 🟰 CROSS (NeoAegis) But... FLOT 💪> ECX (FLOT-4 AIO) So ... FLOT 💪> CROSS ? 🙊

The Lancet Gastroenterology & Hepatology

@LancetGastroHep

9 months

New research - Reynolds et al - Trimodality therapy vs perioperative chemotherapy for locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS phase 3 trial #OncTwitter #GITwitter #EsoCSM

2

77

145

10

18

83

Lizzy Smyth

@LizzySmyth1

3 years

#ESMO21 @myESMO @FilippoPietran4 @CR_UK Promising results in MAYA trial show temozolomide might induce hypermutation in MGMT low MSS mCRC 1/3 oesophageal cancers are MGMT low. We are investigating this approach in the ELEVATE trial @CRUKCamThoracic

2

23

76

Lizzy Smyth

@LizzySmyth1

2 years

👏👏 ESMO22 Upper GI Oral Session 👏👏 @myESMO AIO MOONLIGHT trial in Advanced 1L gastric cancer What we learned: FOLFOX + Nivo-ipi ⬆️⬆️ than FOLFOX then nivo-ipi mOS > 16m for PD-L1 CPS1+ is encouraging ➡️ need 1L chemo anti-CTL4/PD-1 trial

1

17

81

Lizzy Smyth

@LizzySmyth1

3 years

#colorectal #cancer is 📈 in younger patients ➡️ new IDEA/ #EORTC collaboration shows younger patients with Stage III CRC have ⬇️ survival despite receiving ⬆️ chemo. ➡️ need better treatments and earlier detection 👏👏 @ElisaFontana83 and team!

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and...

PURPOSE Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on optimal adjuvant therapy should consider treatment adherence, adverse events, and expected...

ascopubs.org

2

27

79

Lizzy Smyth

@LizzySmyth1

3 years

Here we go!! #ESMO21 non-colorectal mini orals!! @myESMO @YJanjigianMD

0

8

80

Lizzy Smyth

@LizzySmyth1

3 years

DESTINY-Gastric02 #ESMO21 @myESMO Fantastic results for 2L HER2+ #gastriccancer Trastuzumab deruxtecan shows equivalent activity in Western patients compared to Asian trials ORR 40% Median duration of response 8 months DESTINY-Gastric04 opening soon @CRUKCamThoracic

2

19

75

Lizzy Smyth

@LizzySmyth1

6 months

Oh oh.... 🫢 An all female panel in GI oncology! What is the world coming to? Well done TTD 👏🏻👏🏻 Very proud to share the stage with my friends @tfleitask and Maria Alsina in the beautiful city of Cordoba ☺️

Grupo Español de Tratamiento de Tumores Digestivos

@GrupoTTD

6 months

🔴 Arrancamos la tarde con la 3ª Mesa del 31 Simposio Internacional #TTD23 ⏩ CÁNCER ESÓFAGO-GÁSTRICO ✔️ Dra. Tania Fleitas ✔️ Dra. María Alsina ✔️ Dra. Elizabeth Smyth MODERAN: Dra. Paula Jiménez Fonseca y Dr. Ramón Rodríguez Mowbray

0

1

3

1

8

77

Lizzy Smyth

@LizzySmyth1

11 months

📢🆕 #ESMOGI24 📢 Calling all GI oncology colleagues 👩‍⚕️🧑‍⚕️👩‍🔬 See you in Munich next June for a brand new @myESMO meeting!

ESMO - Eur. Oncology

@myESMO

11 months

Mark your agenda for the ESMO Gastrointestinal Cancers Congress 2024 (26-29 June in Munich). For the most impactful new data in #GIoncology , w/ the high-quality educational programme & unrivalled networking opportunities that define ESMO meetings #ESMOGI24

1

28

65

0

11

71

Lizzy Smyth

@LizzySmyth1

2 years

So happy to meet my #EORTC friends in Brussels! Today I was elected next EORTC GI Trials Group Chair 😊 I'd like to say thank you everyone who has supported me on my journey from early career investigator to this role. Now I want to give that support back and #fightcancer

15

2

68

Lizzy Smyth

@LizzySmyth1

3 years

After a great #ESMO21 please join us for on-demand #education : ➡️Maria Alsina @VHIO on HER2/FGFR2/CLD18.2 in #gastriccancer ➡️Patrick Tan @csi_singapore @NUSingapore on RNA & epigenetic predictors of response ➡️ @LizzySmyth1 on immune biomarkers in upper GI trials @myESMO

3

25

68

Lizzy Smyth

@LizzySmyth1

7 months

Not your average scientific meeting... #ESMOAsia23 @myESMO Fantastic opening ceremony with Dragon Dance 🐉! Looking forward to great science and collaboration with our Asian colleagues!

1

5

66

Lizzy Smyth

@LizzySmyth1

3 years

Hanging out online with @myESMO friends at the Virtual #GastricCancer Preceptorship Thank you to our participants for joining us today, to my co-chair @FlorianLordick and today's excellent faculty @tfleitask @ValeGambardella @HannekevanLaar1 #ESMOW4O

1

11

61

Lizzy Smyth

@LizzySmyth1

2 years

And there's more..... ESMO Oesophageal Cancer Guidelines 2022 👏👏 Another brilliant team and a privilege to work with! @RadkaObermanno1 @ArndtVogel @AndresC27622123 @myESMO

0

13

59

Lizzy Smyth

@LizzySmyth1

1 year

#ESDE23 Chemotherapy wins again in CROSS vs FLOT 😆 Just wait until we oncologists add IO with next generation targeted therapy for HER2 and CLD18.2.. Good news for patients! But surgeons might be out of a job 🙊

Lorenzo Ferri MD PhD

@LFerri123

1 year

Outstanding debate on Chemo vs Chemoradiation for esophago- gastric junction cancers between ⁦ @LizzySmyth1 ⁩ and Karin Haustermans ⁦ @esde2023 ⁩. Chemo is winning IMHO. ⁦ @ISDE_net ⁩

1

13

40

3

9

62

Lizzy Smyth

@LizzySmyth1

3 years

Anti-PD-1 is an effective option most but not all MSI #gastriccancer patients. Now we know why. Really great work @KlempnerSam and colleagues 👏👏👏

2

13

60

Lizzy Smyth

@LizzySmyth1

4 years

#ESSO2020 💙Upper GI surgeons and oncologists working together to improve survival for #stomachcancer and #esophagealcancer . 10 year update on the CROSS trial - 13% OS benefit. @polom_karol @ESSOnews @OncoAlert

2

13

58

Lizzy Smyth

@LizzySmyth1

2 years

So pleased to have a great case from our Ukrainian 🇺🇦 colleagues at the @myESMO gastric cancer #preceptorship ! They are delivering excellent care and even running clinical trials under enormous pressure💪. Well done!!

0

6

58

Lizzy Smyth

@LizzySmyth1

8 months

🎯 Another new option for GC/GEJ cancers 👍 Very proud to comment on this important trial with @sundar__raghav in @TheLancet . Immune context matters for combination therapy!

Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oes...

HER2 overexpression or amplification occurs in 17–23% of gastro-oesophageal-adenocarcinoma tumours, driving oncogenesis.1,2 The ToGA trial showed a survival advantage for trastuzumab, an anti-HER2...

www.thelancet.com

Arndt Vogel

@ArndtVogel

8 months

Pembrolizumab, trastuzumab + chemotherapy for HER2-positive GC or GEJ: interim analyses from the phase 3 KEYNOTE-811 @TheLancet 👉Practice changing & already approved by EMA & FDA 😅Don't miss comment by @LizzySmyth1 @myESMO

0

34

71

2

10

58

Lizzy Smyth

@LizzySmyth1

11 months

New EU approval for chemo-trastuzumab-pembro in 1L HER2+ PD-L1+ gastroesophageal #Cancer We haven't seen the survival data yet! Looking forward to peer-reviewing 🕵️‍♀️these results at #ESMO2023 @myESMO

CHMP Supports Approval of Pembrolizumab Plus Trastuzumab/Chemotherapy for HER2+, PD-L1+ Advanced...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy...

www.onclive.com

0

15

54

Lizzy Smyth

@LizzySmyth1

1 year

⏰ Three days to go until the KEYNOTE-859 results are revealed 👀 ⏰ Join @FlorianLordick @BHenickMD and me online at 6pm CET on 16/2 at this #ESMO plenary webinar for a clincal and scientific appraisal of this global phase 3 RCT. @myESMO @AACR

1

10

54

Lizzy Smyth

@LizzySmyth1

2 years

💥 Tislelizumab ⬆️ survival for untreated advanced squamous oesophageal cancer 💥 RATIONALE-306 results at #WCGIC2022 ⬆️ OS by > 6m in PD-L1 CPS>10 and all comers ❓benefit in PD-L1 negative (not shown) ➡️ mixed chemo backbones (+oxali & 5FU free) More options for patients 👍

1

13

52

Lizzy Smyth

@LizzySmyth1

3 years

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | comment: Elizabeth Smyth MD via @practiceupdate Great news for #esophagealcancer patients.... ❓For all-comers, adeno, ESCC or PD-L1 CPS>5?

3

17

54

Lizzy Smyth

@LizzySmyth1

3 years

Now published 👏👏 GO-2 is an important trial; For 👵👴 and frail #gastriccancer and #esophagealcancer patients treatment with ⬇️ dose chemo is safe with ↔️ efficacy ⬆️ QoL. @OncoAlert @practiceupdate via @JAMAOnc part of @JAMANetwork

Efficacy of Reduced-Intensity Chemotherapy Among Older and Frail Patients With Advanced Gastroeso...

This randomized clinical trial assesses the efficacy of reduced-intensity chemotherapy for patient quality of life and cancer control in the treatment of older and/or frail patients.

jamanetwork.com

3

19

51

Lizzy Smyth

@LizzySmyth1

11 months

⏰⏰ Times are changing quickly in #gastric #cancer The new @myesmo Living Guidelines allow us to rapidly update our evidence based recommendations for clinical practice. 📢 There is a new recommendation for trastuzumab deruxtecan for 2L+ HER2 positive patients📢

ESMO - Eur. Oncology

@myESMO

11 months

Just out 📢 The ESMO #GastricCancer Living Guideline. Updates in 1st-, 2nd- & further lines of tx of advanced/metastatic unresectable #OesophagealCancer , #OesophagogastricJunctionCancer & #GastricAdenocarcinoma ; & supportive care & nutrition. 🔗 #esocsm

3

22

45

2

17

51

Lizzy Smyth

@LizzySmyth1

1 year

➡️We need a collaborative PD-L1 Blueprint type study in gastroesophageal adenocarcinoma to be satisfied that we are using a biomarker which is reliable and reproducible.. Watch this space @EORTC @sundar__raghav

2

14

48

Lizzy Smyth

@LizzySmyth1

3 years

👏Great editorial discussing the potential & challenges of ctDNA 🧬 monitoring in adjuvant #gastric and #esophageal #cancer ! @TarazonaNoelia @YJanjigianMD @myESMO @Annals_Oncology @RFitzgerald_lab Postoperative ctDNA monitoring: a canary in a coalmine

Postoperative ctDNA monitoring: a canary in a coalmine

The incidence of esophagogastric (EG) cancer is increasing rapidly, and fewer than 35% of patients with locally advanced disease will survive beyond 5 years.1 The population of patients who receive...

www.annalsofoncology.org

0

14

49

Lizzy Smyth

@LizzySmyth1

3 years

Well done Emma Ococks @RFitzgerald_lab PhD candidate 👩‍🔬 for her excellent work on ctDNA 🧬in resected gastroesophageal cancer What next? We are developing ctDNA guided risk stratified adjuvant trials 💊 @Annals_Oncology @OncoAlert @CRUKCamAero

0

12

50

Lizzy Smyth

@LizzySmyth1

2 years

📢📢 Excellent news for #Gastric #cancer patients 📢📢 Positive PFS and OS results for zolbetuximab in claudin 18.2+ve (40% mGC) 👏👏👏 Really importantly zolbe adds minimal toxicity once nausea 🤢is controlled. Really looking forward to seeing the full results!

Jeroen Dekervel

@JDekervel

2 years

Moving the needle in #GastricCancer . The addition of Zolbetuximab to FOLFOX in 1st line CLDN18.2 positive disease. ⬆️PFS ⬆️OS - eager to see full data

0

5

18

0

14

50

Lizzy Smyth

@LizzySmyth1

2 years

Trastuzumab deruxtecan is a powerful 💥 drug in HER2+ve oesophagogastric cancer. Recent 2L EMA approval based on DESTINY Gastric 02 results is great news for patients ✅ ❓can we replicate TdXD activity in HER2 low GC as seen in HER2 low mBC? Promising ORR but need ⬆️ numbers.

Arndt Vogel

@ArndtVogel

2 years

🧐Is there a role for Trastuzumab-Deruxtecan in HER2–Low Gastric Adenocarcinoma❓ @JCO_ASCO 👉19 pts HER2 IHC 2+/ISH– -> DCR 86% mPFS 4 mOS 8 👉 21 pts HER2 IHC1+-> ORR 62% mPFS 3 mOS 8 🎯promising -> further evaluation wanted @myESMO @OncoAlert

0

25

48

1

18

48

Lizzy Smyth

@LizzySmyth1

1 year

Looking forward to seeing the KEYNOTE 811 results at #ESMO 2023 ✅ PFS endpoint met for **PD-L1 ➕ only** ❓OS.. trend but not there yet... FDA label being amended for PD-L1 status; EMA right to wait?

Yelena Y. Janjigian MD

@YJanjigianMD

1 year

Excited to finally share that Keynote 811 survival data in first line HER2+ gastroesophageal cancer will be presented at @myESMO @MSKCancerCenter @MSK_DeptOfMed

4

46

185

1

9

48

Lizzy Smyth

@LizzySmyth1

2 years

🔥🔥 TdXD as effective in non-Asian population compared to Asian 🔥🔥 DG02 Trial results @ #ESMO22 ➡️ ORR 41.8% ➡️ mOS > 12.1 months Should we have European license? Great discussion by @FlorianLordick @myESMO

0

12

47

Lizzy Smyth

@LizzySmyth1

4 years

Thank you @AndresC27622123 for the invitation to write this discussion with you on #ESMO2020 immunotherapy results! Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer

2

8

47

Lizzy Smyth

@LizzySmyth1

4 years

After a champion 🏆 #ESMO2020 for immunotherapy in #gastric and #oesophageal cancer; is adjuvant nivolumab post CRT + surgery the right treatment for ALL patients? @DrRonanKelly and Salah Al-Batran debate at #ESMO2020 Educational weekend 💥💥! Join at

ESMO - Eur. Oncology

@myESMO

4 years

Don't miss the #ESMO20 Education weekend kick-off 16/10 (9:35 CEST): 📌Upper GI: Are CheckMate 577 results applicable to both EC & GEJC pts? 📌GU: Is comb VGEF-R TKI + immune checkpoint or dual immune checkpoint modulation the way to go? 👉Access here:

0

11

19

1

4

46

Lizzy Smyth

@LizzySmyth1

3 years

This is innovative and important work in @JCO_ASCO from @sundar__raghav Computational analysis can accurately derive unpublished subgroup results in clinical trials 🤯🤯 ! This approach has the potential to be a game changer! Well done 👏👏 @OncoAlert @VJOncology @myESMO

Raghav Sundar

@sundar__raghav

3 years

Pleased to present data that most GI oncologists have been asking for, but not gotten so far: role of Nivolumab in CPS 1-4 gastric cancer. Answer: Minimum to none. EMA has restricted approval to only CPS >= 5. What about FDA?

2

24

84

2

16

45

Lizzy Smyth

@LizzySmyth1

3 years

It's here! #ESMO21 🎉🎉 Today in #gastriccancer and #esophagealcancer : 💥💥 Controversy at 14:20 CET: Chemoradiotherapy for all gastroesophageal cancer? Yes: Prof J Reynolds (Neo-Aegis) No: @YJanjigianMD Moderator @FlorianLordick Which side has your vote ☑️? @myESMO

0

9

47

Lizzy Smyth

@LizzySmyth1

7 months

Here we go! Join me and @sundar__raghav and @KoheiShitara in 402 now for all the latest in #gastric #cancer at #ESMOAsia23

0

1

46

Lizzy Smyth

@LizzySmyth1

4 years

Pembro in 1L #GastricCancer Win, lose or draw? Read the KEYNOTE-062 results and our editorial @JAMAOnc . Looking forward to #ESMO2020 for more exciting trial results!!!

JAMA Oncology

@JAMAOnc

4 years

How do we put the results of the KEYNOTE-062 trial of pembrolizumab vs chemotherapy or pembro/chemo combo as first line therapy for loc adv gastric or GE junction cancer into context? Editorial reviews data & clinical implications #GICSM

0

9

19

2

10

46

Lizzy Smyth

@LizzySmyth1

6 months

🔥 Did I mention cellular therapy is coming to GI cancer? Great update by Changson Qi on status of CAR-T at #ESMOImmuno23

1

9

46

Lizzy Smyth

@LizzySmyth1

1 year

World GI Barcelona Jun 28-Jul 1 The best oncology & science 👩‍🔬🧬 in a gorgeous setting ☀️💃 Gender balanced ⚖️ programme in the works from the hard working scientific committee There are travel ✈️🚝 awards for junior faculty and developing country abstracts so please submit!

World Congress on Gastrointestinal Cancer

@WCGIC

1 year

The Wait Is Over. The #WCGIC2023 agenda is now live! Explore the extensive scientific programme and register to join your colleagues in Barcelona from 28 June - 1 July. #Patientswin #clinicalresearch #data #oncology #gastrointestinalcancer @myESMO

0

4

15

0

11

45

Lizzy Smyth

@LizzySmyth1

2 years

Thanks to everyone who joined our #ESMO #Gastric #Cancer Webinar Great talks from @FlorianLordick & @RADUVIDRA 👏👏 Gastric cancer docs are smart! Really informed questions from attendees. ➡️Looking forward to interacting more at our #preceptorship in Valencia this weekend!

2

3

44

Lizzy Smyth

@LizzySmyth1

2 years

🇫🇷 #ESMO22 🇫🇷 je suis arrivée (almost!) On the🚄 #traintoesmo and looking forward to seeing my @ESMO friends 😀 Join @stephenchan1 , Jennifer Knox and Thierry Conroy and me for our Updates on Peri-op and Adjuvant for UGI Cancers at 4pm in Cannes Auditorium for a great session!

0

1

42

Lizzy Smyth

@LizzySmyth1

6 months

Oncology = communication So pleased to work with @dice_europe and @myESMO to develop the ESMO patient guides for #OesophagealCancer & #GastricCancer .

ESMO - Eur. Oncology

@myESMO

6 months

Highlights from the launch of the ESMO Patient Guides on #OesophagealCancer & #StomachCancers . @LizzySmyth1 , Florian Lordick, Radka Obermannová, Tihana Gašpert & Zorana Maravic discussed what is important to patients, relatives & caregivers. @dice_europe

0

2

11

2

5

46

Lizzy Smyth

@LizzySmyth1

8 months

What happens when #ESMO 🇪🇺🇮🇪🇬🇧 goes to #ASCO 🇺🇸? Join me and an amazing panel of speakers to discuss new targets 🎯 in gastroesophageal cancer at this #ASCO plenary on 7th November!

Toni Choueiri, MD

@DrChoueiri

8 months

JUST IN: The November @ASCO #ASCOPlenarySeries => 2 NEW #GI cancers Clinical trials! NOVEMBER 7th 3pm EST (FREE!): Link: Because...."Science can't (and shouldn't) wait"! @SoniSmithMD @SalemGIOncDoc @DrMMurphy @MLJohnsonMD2 @DannyGrayson913 @ASCOPres

0

15

29

0

5

39

Lizzy Smyth

@LizzySmyth1

2 years

📢📢 The great upper GI PD-L1 debate! 📢📢 #ESMO22 @myESMO Join us @3pm in 7.2 Fecamp today! @YJanjigianMD @sundar__raghav

0

6

40

Lizzy Smyth

@LizzySmyth1

10 months

Save the best til last! #ESMOAcademy23 rounded up by an awesome Upper GI session 👏 Thanks to @myESMO for the invite to speak. So great to see @DrAngelaLamarca even as Spain Vs England ⚽⚽ ongoing!

Angela Lamarca

@DrAngelaLamarca

10 months

Who said that you cannot #summarise the whole #upperGI and #HPB in 1 hour? Just happened during #ESMOAcademy23 🥳 in #Zurich ! My pleasure to share the stage with @LizzySmyth1 . We are great duo 😉 Remember - #ESMOGI24 in #Munich (June2024)! @myESMO

1

5

70

2

4

39

Lizzy Smyth

@LizzySmyth1

2 years

⏰One week until ESMO Colorado⏰ Looking forward to the 1st ESMO Colorado Conference at the Hilton Denver Inverness! Please join us for FREE in-person or virtually. 📅 Oct. 15-16, 2022 Register for free at: @TotalHealthConf @myESMO

0

8

38

Lizzy Smyth

@LizzySmyth1

1 year

What's going on in #gastric and #esophageal #cancer ? Join me, @YJanjigianMD & @KlempnerSam live on 28th of March to discuss the latest practice changing trials and research 🔬💊 Looking forward to your questions!

Yelena Y. Janjigian MD

@YJanjigianMD

1 year

Register for this online live seminar March 28th covering all the current topics in esophagus and stomach cancer. Looking forward to the discussion with @LizzySmyth1 @KlempnerSam @MSKCancerCenter @MSK_DeptOfMed @OncoAlert

0

4

29

0

8

37

Lizzy Smyth

@LizzySmyth1

1 year

......but PD-L1 can be an unreliable biomarker in gastroesophageal adenocarcinoma

2

5

39

Lizzy Smyth

@LizzySmyth1

6 months

Where melanoma goes first, oesophagogastric cancer goes later (I hope..) ☑️Encouraging long-term results for TIL in ICI-pretreated melanoma @ #ESMOImmuno23 @myESMO If any TIL researchers are interested in gastric cancer do get in touch!

0

8

39

Lizzy Smyth

@LizzySmyth1

4 years

These are not the type of Kaplan-Meier curves I like to see 🤦‍♀️ I am glad to work with so many great women and supportive men but we need to do better. Women Physicians and Promotion in Academic Medicine | NEJM

1

3

35

Lizzy Smyth

@LizzySmyth1

1 year

⏰Today is the day!⏰ Real life is sometimes more complicated than guidelines... Join me and our wonderful panel at 6.30pm CET to discuss how best to treat #oesophagealcancer based on the @myesmo guidelines

ESMO - Eur. Oncology

@myESMO

1 year

#OesophagealCancer webinar airing tomorrow (29/3) 👉 a unique opportunity to learn from the ESMO Guideline experts & get your questions answered. 29 Mar, 18:30 CEST Access with your free ESMO account: @LizzySmyth1 @RadkaObermanno1 #EsophagealCancer #esocsm

0

10

20

0

7

36

Lizzy Smyth

@LizzySmyth1

1 year

What a great inaugural meeting! #UKIOG2023 👏👏 Here's Sarah Gwynne discussing the future of PIPAC in the UK Thanks to everyone for getting involved and to our industry sponsors 🙏

0

5

36

Lizzy Smyth

@LizzySmyth1

2 years

📢📢 #ESMO Gastric Cancer Guidelines Webinar 📢📢 When #Guidelines meet #RealLife what do the experts do? ⏰ 25th October 5.30pm GMT / 6.30pm CET ⏰ @myESMO

ESMO - Eur. Oncology

@myESMO

2 years

#Gastriccancer : Join the experts developing and implementing ESMO Guidelines for best practice recommendations applied to a real-world case. Register now for free and get 1 ESMO-MORA point. ⏰ 25 Oct at 18:30 CEST 🔗 @FlorianLordick @LizzySmyth1 @RADUVIDRA

0

7

24

1

14

35

Lizzy Smyth

@LizzySmyth1

3 years

The Oncology PRO Working Group is responsible for keeping the @myESMO OncologyPRO website content high quality and up-to-date. I'll be chairing the group for the next two years and we are looking for new members. Please join us!

ESMO - Eur. Oncology

@myESMO

3 years

The ESMO OncologyPRO Working Group is looking for 3 ESMO members to join this dynamic group by the beginning of 2022 - a unique opportunity to contribute to ESMO's digital educational activities & LT developmt of OncologyPRO Full details 👉 @LizzySmyth1

0

2

6

0

7

34

Lizzy Smyth

@LizzySmyth1

2 years

So pleased to meet new and old friends at #ESMO Latin America Summit 😊! Great gastric and esophageal cancer session with a sneak peak 👀at the new #esmoguidelines ! @myESMO @FlorianLordick

Juan OConnor

@Juanmaoconnor

2 years

A Big Thanks @LizzySmyth1 and @FlorianLordick for sharing your knowledge and also support this ESMO SUMMIT LATAM! It was a great experience 😊

3

4

38

0

3

33

Lizzy Smyth

@LizzySmyth1

3 years

It's a privilege to be able to report from #ESMO21 in Paris! ✅Cutting edge trials ✅ Great friends ➡️➡️ ESMO #Community Thanks @myESMO for the opportunity!

ONCOassist® | The go-to oncology app

@ONCOassist

3 years

Let's take a look at the #ESMO21 top influencers on Day 4 on Twitter. @bryanfvc96 @ShannonWestin @1969carodriguez @LizzySmyth1 @AzadOncology @bradloncar @teamoncology @EfstathiouEleni @DrMHofman

1

10

25

1

2

34

Lizzy Smyth

@LizzySmyth1

1 year

Looking forward to seeing all my GI friends at #ESMO #WGIC23 next week in #Barcelona !

Cure GI Cancers

@RueschCenter

1 year

In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer with @marshalj23 , @LizzySmyth1 , and @mariglesiascoma . via @ReachMD

0

2

6

0

2

33

Lizzy Smyth

@LizzySmyth1

4 years

Great work in @CD_AACR from @DocCatenacci on the PANGEA trial of personalised targeted therapy for #stomachcancer and #esophagealcancer . ✅ This is the way forward for trial design in small biomarker selected groups. @OncoAlert @mery80878696 @RussellPetty19 @FlorianLordick

Elizabeth McKenna

@ElizSMcKenna

4 years

Just out in @CD_AACR : Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): a phase 2 study evaluating an individualized treatment strategy for metastatic disease @DocCatenacci @UCCancerCenter #ClinicalTrial #GastricCancer #EsophagealCancer

1

11

45

0

10

31

Lizzy Smyth

@LizzySmyth1

4 years

Great to see my good friends @ValeGambardella and Maria Alsina as faculty at #ESMO Gastric Cancer Preceptorship 👏👏 #WomenInMedicine @myESMO @FlorianLordick @AndresC27622123

2

4

31

Lizzy Smyth

@LizzySmyth1

4 years

It's time to digest the latest news on #Immunotherapy from #ESMO2020 ! ▶️ @DocCatenacci and I review the data on @practiceupdate .

PracticeUpdate

@practiceupdate

4 years

Adding #Immunotherapy to First-Line Chemotherapy for #EsophagealCancer : Data and Implications From KEYNOTE-590. 📽️ @myESMO #ESMO20 interview by @LizzySmyth1 of @DocCatenacci 🔽 #esocsm

0

2

8

1

7

30

Lizzy Smyth

@LizzySmyth1

4 years

💥💥💥!! @DocCatenacci has done an amazing #tweetorial on #ESMO2020 data on immunotherapy in #stomachcancer and #esophagealcancer . Asking the right questions🕵️🕵️🔎 Who benefits and why?

Daniel Catenacci

@DocCatenacci

4 years

Ok...Honeymoon is over & now time to dissect the exciting new data presented @ #ESMO2020 for #GEC #KN590 #CM649 #ATTRCN4 #CM577 1st, thank you to all the pts who participated! & 2nd, congrats to all the investigators involved! It's fantastic to have +ve studies! Lets dive deep:

15

42

128

0

5

30

Lizzy Smyth

@LizzySmyth1

1 year

The benefit of pembrolizumab plus chemotherapy is ⬆️ in CPS >10 (HR 0.64) and much ⬇️ (HR 0.92) in PD-L1 negative patients

1

6

30

Lizzy Smyth

@LizzySmyth1

3 years

#ESMO21 Non-colorectal mini oral 17.30 CET Looking forward to LBA55: First report of trastuzumab deruxtecan efficacy in Western patients! Also efficacy of immune checkpoint inhibitors in #gastriccancer and #esophagealcancer ➡️evolving better options for patients @myESMO

0

6

26

Lizzy Smyth

@LizzySmyth1

4 years

What a great session with an enthusiastic bunch of young oncologists #YOC from all over the world #ESMO is truly a global 🌍 organisation. Thank you for the invitation @rillepihlak & @TeresaSAmaral @myESMO

Federico Nichetti

@fedenichetti

4 years

It was a brilliant GI cancers case discussion, thanks @LizzySmyth1 and @myESMO !! @A_DAlessioMD @rillepihlak @TeresaSAmaral

0

2

15

0

4

26

Lizzy Smyth

@LizzySmyth1

2 years

It's wonderful to see everyone in person again at last! #ESMO #preceptorship #IO I'm learning lots and having new ideas already in the basic science talks 🤓! @myESMO

Teresa Amaral, MD, PhD

@TeresaSAmaral

2 years

@myESMO #IO #preceptorship starting now! Chaired by @HaanenJohn @peters_solange & Rolf Stahel. What a pleasure to be here with so many great colleagues 😀 and...to see so many #Portuguese colleagues in the audience 😊

0

6

34

0

26

Lizzy Smyth

@LizzySmyth1

2 years

Brilliant session this with the #ESMOYOC at #WCGIC this morning 👏👏 Great to see so many young doctors interested in a career in academic oncology!

Claudia Cardone

@clacardone

2 years

🦜Outstanding presentations at #ESMOYOC session this morning #WCGIC2022 @AndresC27622123 @EMariamidze 🔅Predictive biomarkers in GI Cancers, @LizzySmyth1 @TarazonaNoelia 🔅Mentorship part @ChiaraCrem1 #JoaquinMateo @ESMOWorldGI @myESMO Meet you at 17.15 at Lounge session !

1

7

48

0

1

26

Lizzy Smyth

@LizzySmyth1

3 years

It's always a pleasure to work with my Italian buddies! 🇮🇪❤️🇮🇹

Filippo Pietrantonio

@FilippoPietran4

3 years

Happy to share our meta-analysis of RCTs on MSI & immunotherapy in metastatic gastric cancer #msi #immunotherapy #GC @LizzySmyth1 @JoeChaoMD @faupe @ESMO_Open

0

8

21

3

0

25

Lizzy Smyth

@LizzySmyth1

8 months

Surgeons! 👩‍⚕️👨‍⚕️ Please do consider a job in UGI in Oxford below. These guys are a truly great bunch - pushing the boundaries in every direction. Oncologists not bad either 😜

Sheraz Markar

@MarkarSheraz

8 months

Please consider joining our great UGI unit in Oxford. Exciting opportunity to work with a growing dynamic oesophago-gastric unit.

3

10

33

0

8

24

Lizzy Smyth

@LizzySmyth1

2 years

On my way ✈️to #AUGIS in #Aberdeen today Looking forward to our session @RussellPetty19 @MarkarSheraz @TimTheSurgeon UK UGI oncologists❤️UGI surgeons - working together to improve outcomes for oesophageal cancer patients.

1

2

23

Lizzy Smyth

@LizzySmyth1

1 year

📢 Are you interested in #ESMO and digital education? Join us in the #OncologyPRO working group @myesmo There are plenty of places available so don't be shy and get stuck in!

ESMO - Eur. Oncology

@myESMO

1 year

ESMO Members get involved 📢 OncologyPRO Working Group Open Call for Working Group Members: take this unique opportunity to contribute to the development of digital educational activities within ESMO & OncologyPRO's long-term journey. Deadline: 6 Feb

1

4

11

0

8

23

Lizzy Smyth

@LizzySmyth1

3 years

Great artwork @ElisaFontana83 !

Cancer Discovery

@CD_AACR

3 years

In the Spotlight: Dissecting response and resistance to anti-PD-1 therapy in microsatellite unstable #gastriccancer . @LizzySmyth1

1

11

33

1

8

22

Lizzy Smyth

@LizzySmyth1

3 years

@DocCatenacci @RussellPetty19 @SteveMaronMD @luckydoc2 @LFerri123 @OncoAlert @GI_OncologyHub @KlempnerSam @JoeChaoMD @pashtoonkasi CROSS = MAGIC No surprises here! FLOT 🏆 (but still only cures 50% so we need to do better).

1

2

23

Lizzy Smyth

@LizzySmyth1

3 years

➡️ Important research from UK gastroesophageal cancer audit 📌>4000 patients treated with surgery + chemo for operable cancer 📌Adjusted for known confounders patients who had post-op chemo after neoadjuvant chemo + surgery had ⬆️survival ➡️ Give the adjuvant chemo if possible

Saqib Rahman

@SaqRahman

3 years

Great to see our most recent NOGCA paper published open access in the BJS today: . This has been a labour of love with help from @TimTheSurgeon @maynard_nick @tomcrosby12 and many others at the NOGCA.

3

24

51

2

10

23

Lizzy Smyth

@LizzySmyth1

4 years

Sign up below for this great online meeting to hear the latest science 🧬🔬🧪in #stomachcancer and #esophagealcancer . See you there🤓! @RussellPetty19 @FlorianLordick @ValeGambardella @tfleitask @AndresC27622123

Yelena Y. Janjigian MD

@YJanjigianMD

4 years

Please join us! I am looking forward to it! #criticalmass in EG cancer #research . @DocCatenacci @LizzySmyth1 @SteveMaronMD @RyanMoyMDPhD @LumishMelissa

0

1

18

0

5

22

Lizzy Smyth

@LizzySmyth1

2 years

❓Chemo or not for 1L ESCC? ➡️ How do you decide? First read @FlorianLordick and I debate (nicely🥊🥊 ) in @TheLancetOncol ...

The Lancet Oncology

@TheLancetOncol

2 years

Perspective – Spotlight debate: Should #chemotherapy -free treatment be offered for advanced #oesophageal squamous-cell #carcinoma ? @LizzySmyth1 argues NO @FlorianLordick argues YES

0

6

16

0

11

22

Lizzy Smyth

@LizzySmyth1

4 years

100% agree with this excellent perspective by @DVAraujoMD and @lillian_siu . It's time to innovate in clinical trial design and delivery. via @JAMAOnc part of @JAMANetwork

0

8

20

Lizzy Smyth

@LizzySmyth1

3 years

ORIENT-15 ESCC anti-PD-1 (sintilimab) ⬆️OS vs chemo ⬆️⬆️in PD-L1 CPS >10 ORIENT-16 GEA anti-PD-1 (sintilimab) ⬆️OS vs chemo ⬆️⬆️ in PD-L1 CPS >10 Consistent evidence of an immune sensitive population in #esophageal and #gastriccancer #ESMO21 @myESMO

Anti-PD-1 for all ESCC?

17

Anti-PD-1 for CPS >10

38

1

6

20

Lizzy Smyth

@LizzySmyth1

2 years

So happy to catch up with @iaintan_mdphd at the excellent #AGIGT22 We first met as trainees more than a decade ago. Look how far we've come! Thanks to #AGIGT for the invitation to speak. The group's work in #CancerResearch is inspiring 👏👏

1

3

21

Lizzy Smyth

@LizzySmyth1

2 years

@antonyruggeri @ILSONDavid @YJanjigianMD @FlorianLordick @DocCatenacci Right now the options we discuss at MDT are: ➡️Continue FLOT with limited expectations of efficacy (but does tumour = micrometastatic disease?) ➡️Enroll in VESTIGE trial (FLOT vs nivo-ipi) What we should be doing in future ✅ ctDNA based trials

2

20

Lizzy Smyth

@LizzySmyth1

1 year

I'm very proud of the UK Sarah Cannon physician leader at 0:50! 👏👏 Happy International Women's Day! 👩‍⚕️👩‍🔬🧑‍🚀👮‍♀️🧑‍🏫🧑‍💼🧑‍⚖️🧑‍🚒👩‍👧

Sarah Cannon Docs

@SarahCannonDocs

1 year

In celebration of International Women’s Day, physician and operational leaders from across our network are sharing how they strive to “Embrace Equity” every day. How do you plan to Embrace Equity for women this year?

0

2

8

0

1

21

Lizzy Smyth

@LizzySmyth1

3 years

@AndresC27622123 @myESMO Andres, there some who just "talk the talk" but not you! You truly have given so much support to young women in oncology. Bravo for "walking the walk" 👏👏👏 #leadership

2

20

Lizzy Smyth

@LizzySmyth1

10 months

Looking forward to seeing my @myESMO friends in Zurich at #ESMOAcademy23 ! It's always fun to meet the next generation of young oncologists!

ESMO - Eur. Oncology

@myESMO

10 months

#ESMOAcademy23 kicking off today in Zurich 📣 exploring key topics in #medicaloncology , such as methodology and interpretation of clinical trials, standard of care and future perspectives in main tumour types, pharmacokinetics and drug interactions.

2

8

55

0

20

Lizzy Smyth

@LizzySmyth1

11 months

💯 this 👇

lucy gossage

@lucygoss

11 months

I’m an oncologist and I love my job. But I’m striking because I know first-hand that the NHS is failing our patients with cancer and I’m striking because I know first-hand that the NHS is failing its workforce. #ConsultantsStrike

139

1K

4K

0

3

20

Lizzy Smyth

@LizzySmyth1

3 years

#ESMO21 @myESMO @JenSeligmann CRC Orals Pierre Laurent Puig has done a great job putting FOCUS4 results in context 👏👏👏

0

7

19